Picture of Mauna Kea Technologies SA logo

ALMKT — Mauna Kea Technologies SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Mauna Kea Technologies Announces Positive Results From Interstitial Lung Disease Trial

Oct 17 (Reuters) - Mauna Kea Technologies SA  ALMKT.PA :
    * PUBLICATION OF POSITIVE RESULTS OF A RANDOMIZED CONTROLLED
TRIAL
IN FIELD OF INTERSTITIAL LUNG DISEASE
    * MAUNA KEA TECHNOLOGIES ANNOUNCES PUBLICATION OF POSITIVE
RESULTS
OF A RANDOMIZED CONTROLLED TRIAL IN FIELD OF INTERSTITIAL LUNG
DISEASE
    * SUPERIORITY IN PRECISION AND SAFETY OF CELLVIZIO-GUIDED
TRANSBRONCHIAL CRYOBIOPSY FOR DIAGNOSIS OF INTERSTITIAL LUNG
DISEASE (ILD)
    * TRIAL, CONDUCTED BETWEEN JANUARY AND NOVEMBER 2022,
INVOLVED 80
PATIENTS WITH UNDIAGNOSED ILD AND REQUIRING A BIOPSY

Source text for Eikon:  ID:nBw16KDHGa 
Further company coverage:  ALMKT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Mauna Kea Technologies SA

See all news